[go: up one dir, main page]

GB202213032D0 - Dosage regime - Google Patents

Dosage regime

Info

Publication number
GB202213032D0
GB202213032D0 GBGB2213032.2A GB202213032A GB202213032D0 GB 202213032 D0 GB202213032 D0 GB 202213032D0 GB 202213032 A GB202213032 A GB 202213032A GB 202213032 D0 GB202213032 D0 GB 202213032D0
Authority
GB
United Kingdom
Prior art keywords
dosage regime
regime
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2213032.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptimmune Ltd
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Priority to GBGB2213032.2A priority Critical patent/GB202213032D0/en
Publication of GB202213032D0 publication Critical patent/GB202213032D0/en
Priority to EP23734353.8A priority patent/EP4539874A1/en
Priority to US18/874,958 priority patent/US20250367289A1/en
Priority to CA3252728A priority patent/CA3252728A1/en
Priority to JP2024573339A priority patent/JP2025522420A/en
Priority to PCT/GB2023/051565 priority patent/WO2023242578A1/en
Ceased legal-status Critical Current

Links

GBGB2213032.2A 2022-06-16 2022-09-07 Dosage regime Ceased GB202213032D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB2213032.2A GB202213032D0 (en) 2022-09-07 2022-09-07 Dosage regime
EP23734353.8A EP4539874A1 (en) 2022-06-16 2023-06-15 Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
US18/874,958 US20250367289A1 (en) 2022-06-16 2023-06-15 Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
CA3252728A CA3252728A1 (en) 2022-06-16 2023-06-15 Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
JP2024573339A JP2025522420A (en) 2022-06-16 2023-06-15 Dosing regimen for combination therapy consisting of engineered T cells and PD-1 axis binding antagonists
PCT/GB2023/051565 WO2023242578A1 (en) 2022-06-16 2023-06-15 Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2213032.2A GB202213032D0 (en) 2022-09-07 2022-09-07 Dosage regime

Publications (1)

Publication Number Publication Date
GB202213032D0 true GB202213032D0 (en) 2022-10-19

Family

ID=83933368

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2213032.2A Ceased GB202213032D0 (en) 2022-06-16 2022-09-07 Dosage regime

Country Status (1)

Country Link
GB (1) GB202213032D0 (en)

Similar Documents

Publication Publication Date Title
GB2595776B (en) Therapeutic solid dosage forms
IL291453A (en) Dosage forms for tyk2 inhibitors
GB202020191D0 (en) Pharmaceutical compounds
IL308389A (en) Dosage regimens for ecubectedin
GB202010408D0 (en) Pharmaceutical compounds
GB202010409D0 (en) Pharmaceutical compounds
GB202200753D0 (en) Pharmaceutical compounds
GB202111193D0 (en) Pharmaceutical compounds
GB202104097D0 (en) Pharmaceutical compounds
GB202213032D0 (en) Dosage regime
GB202212323D0 (en) Dosage regime
GB202208849D0 (en) Dosage regime
IL315178A (en) Dosage regimen
IL323748A (en) Dosage
GB202102602D0 (en) Pharmaceutical compounds
HK40107495A (en) Dosage regime
GB202006819D0 (en) Dosage regimen
GB202316063D0 (en) Dosing regime
GB202304987D0 (en) Combination pharmaceutical
GB202216306D0 (en) Combination pharmaceutical
GB202203093D0 (en) Medicament
CA235942S (en) Tablet
IL289020A (en) Antibacterial dosage regime using cannabinoids
GB202312534D0 (en) Pharmaceutical compounds
GB202311227D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)